Medication Use Evaluation (MUE) for Continuous Heparin Infusions in Hospitalized Patients
- Conditions
- Unfractionated Heparin
- Registration Number
- NCT06096064
- Lead Sponsor
- Methodist Health System
- Brief Summary
Unfractionated heparin (UFH) is an anticoagulant to prevent thrombus formation or worsening of an existing thrombus. It is indicated for patients with deep vein thrombosis/pulmonary embolism (DVT/PE) or acute coronary syndrome (ACS). Unfractionated heparin treatment consists of an initial bolus followed by a continuous infusion that is adjusted based on the patient's subsequent partial thromboplastin time (PTT) levels
- Detailed Description
Unfractionated heparin is classified as a high-alert medication in the acute care setting.3 Therapeutic anticoagulation is a high priority for healthcare teams because the impacts of inadequate anticoagulation can lead to life threatening events such as a major bleed or thrombus formation and/or death.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
- Patient's aged 18 years or older with a confirmed diagnosis of DVT/PE based on imaging or a confirmed diagnosis of ACS requiring heparin therapy
- History of bleeding in the last 30 days
- History of HIT
- Use of systemic anticoagulants for another indication
- Presence of coagulation disorder prior to admission (i.e. hemophilia, sickle cell anemia, etc.)
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidents of deviations from protocol 30 Days Appropriate anticoagulation management will be measured using Percent time in therapeutic range based on aPTT levels
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Methodist Richardson Medical Center
🇺🇸Dallas, Texas, United States